Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Psychopharmacologic agent"'
Autor:
Tagbo Arene, Calvin Flowers
Publikováno v:
International Journal of Integrated Care; Vol 18: APIC Conference Supplement 2017; 142
Introduction: A significant proportion of individuals with psychotic illness are either refractory to, or intolerant of, standard antipsychotic pharmacotherapy. There is currently only one medication available with proven effectiveness in this popula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f009f259947fe339b3377afc3b0ae20
https://www.ijic.org/jms/article/view/4130
https://www.ijic.org/jms/article/view/4130
Autor:
Jillian M. Orlando
Publikováno v:
The Veterinary clinics of North America. Small animal practice. 48(3)
Behavioral problems of companion animals are becoming more widely recognized. As a result, there are a growing number of behavioral nutraceuticals and diets on the market. These products may be useful for the treatment of mild conditions, for clients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83cbefbb7139187c348450a7d11c6ad4
https://pubmed.ncbi.nlm.nih.gov/29429599
https://pubmed.ncbi.nlm.nih.gov/29429599
Publikováno v:
Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology. 25:193-206
Information on the use of N-acetylcysteine (NAC) in neuropsychiatric disorders has increased in recent publications. Although there are positive reports on the use of NAC in obsessive-compulsive and related disorders (OCRD), such data have not yet be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62426f524aea45789d84b1ad0702fb3b
https://doi.org/10.5455/bcp.20140811064455
https://doi.org/10.5455/bcp.20140811064455
Autor:
Rachel Yehuda, Julia A. Golier
Publikováno v:
Biological Psychiatry. 84:5-6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::254e1d6e49ffd5f0496f6d5273e3a3d8
https://doi.org/10.1016/j.biopsych.2018.05.004
https://doi.org/10.1016/j.biopsych.2018.05.004
Autor:
Jessica M. Henry, Matthew A. Fuller
Publikováno v:
Journal of Pharmacy Practice. 24:447-451
Asenapine is a new psychopharmacologic agent approved for the acute and maintenance treatment of schizophrenia and the acute and maintenance treatment of manic and mixed episodes associated with bipolar I disorder. The efficacy of asenapine in treati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::642877df6ad734b15f48b16bae2a4fae
https://doi.org/10.1177/0897190011422875
https://doi.org/10.1177/0897190011422875
Autor:
Kenneth R. Silk
Publikováno v:
Journal of Psychiatric Practice. 17:311-319
Patients with borderline personality disorder (BPD) are a challenge to treat both psychotherapeutically and psychopharmacologically. While a set of effective psychotherapeutic interventions for BPD has now emerged, no hard evidence exists concerning
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8833687563d411582722b9142fa9dbaf
https://doi.org/10.1097/01.pra.0000405361.88257.4a
https://doi.org/10.1097/01.pra.0000405361.88257.4a
Publikováno v:
European Neuropsychopharmacology. 19:177-187
Asenapine is a psychopharmacologic agent being developed for schizophrenia and bipolar disorder. This study electrophysiologically characterized the in vivo effects of asenapine at dorsal raphe nucleus (DRN) and hippocampus serotonin-1A (5-HT(1A)), v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d82dae10dce2f8bc91e88c4da19d6c09
https://doi.org/10.1016/j.euroneuro.2008.11.001
https://doi.org/10.1016/j.euroneuro.2008.11.001
Publikováno v:
Journal of Psychopharmacology. 23:65-73
Asenapine is a novel psychopharmacologic agent under development for the treatment of schizophrenia and bipolar disorder. We determined and compared the human receptor binding affinities and functional characteristics of asenapine and several antipsy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d5403077dc8321d6bb1825079cb54b4
https://doi.org/10.1177/0269881107082944
https://doi.org/10.1177/0269881107082944
Publikováno v:
Psychopharmacology. 198:103-111
The novel psychopharmacologic agent, asenapine, has high affinity for a range of receptors including the dopaminergic receptors.We examined the long-term effects of multiple doses of asenapine on dopamine receptor subtypes: D(1)-like (D(1) and D(5)),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d460182ae3377a4faa67b6d8ebae3531
https://doi.org/10.1007/s00213-008-1098-7
https://doi.org/10.1007/s00213-008-1098-7
Publikováno v:
The Journal of Clinical Psychiatry. 68:1492-1500
OBJECTIVE This 6-week trial assessed the efficacy, tolerability, and safety of the investigational psychopharmacologic agent asenapine versus placebo and risperidone in patients with acute schizophrenia (DSM-IV criteria). METHOD In a study conducted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::494f3dadedd9f05df6526ff5fbf8d016
https://doi.org/10.4088/jcp.v68n1004
https://doi.org/10.4088/jcp.v68n1004